Ceribell Inc. Chief Technology Officer Raymond Woo sold 1,979 shares of common stock on August 21, 2026, for a total of $47,535 at $24.02 per share to cover tax withholding obligations tied to the vesting of restricted stock units.
Woo’s direct holdings after the transaction stand at 194,729 shares, which includes 1,026 shares acquired under the company’s Employee Stock Purchase Plan on July 31, 2026. The stock was trading near its 52-week high of $25.33 at the time of the sale, following a 109% increase over the past 12 months.
The transaction occurred as Ceribell reported fiscal 2026 second-quarter revenue of $28.1 million, a 33% increase year-over-year, alongside a loss of $0.51 per share. Analysts had anticipated a narrower loss of $0.36 per share. The company added 32 accounts during the quarter, short of Canaccord’s estimate of 36.
Ceribell’s growth is driven by expansion in seizure-detection, new product development in delirium monitoring and pediatric care, and strong same-store utilization. The company also noted recent FDA approvals for pediatric and neonatal indications.
Analysts have adjusted price targets accordingly. Canaccord raised its target from $25 to $26 while maintaining a Buy rating, while BTIG increased its target from $28 to $30.
